Most Read Articles
Audrey Abella, 16 Feb 2017
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) during acute respiratory infection episodes may increase the risk of acute myocardial infarction (MI), a recent study from Taiwan shows.
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Pearl Toh, 01 Mar 2016
Asthma development in young children may be associated with paracetamol exposure during maternal pregnancy or infancy, a new study on the MoBa* cohort showed.
Jairia Dela Cruz, 21 Jun 2017
Control treatment with montelukast may effectively reduce acute exacerbations in preschool children with mild persistent asthma, according to a study from Japan.

Dyspnoea a potential marker of frailty, adverse outcomes in older adults

16 Jul 2017

Dyspnoea commonly occurs in adults aged 80 years and older, and is an independent predictor of mortality, hospitalization and disability, a study has found. Moreover, dyspnoea correlates with cardiopulmonary and physical performance impairments.

The study included 565 community-dwelling older adults (mean age 84.72 years; 62.8 percent female) from the BELFRAIL prospective cohort. Assessments included Medical Research Council dyspnoea scale (MRC), forced expiratory volume in 1 s (FEV1), N-terminal pro-brain natriuretic peptide (NT-proBNP), physical performance tests, grip strength, 15 items geriatric depression scale, activities of daily living (ADL), body mass index (BMI) and demographics data.

Kaplan–Meier survival curves, Cox and logistic multivariable regression, classification and regression tree (CART) analyses were performed to examine the association of dyspnoea (MRC 3 to 5) with time-to-cardiovascular and all-cause death (5 years), time to first hospitalisation (3 years), new/worsened ADL disability (2 years), and its correlates.

Results revealed that older adults with dyspnoea (29.9 percent) were at increased risk of cardiovascular mortality (hazard ratio [HR], 2.85; 95 percent CI, 1.93 to 4.20), all-cause mortality (HR, 2.04; 1.58 to 2.64) and first hospitalisation (HR, 1.72; 1.35 to 2.19), as well as a higher likelihood of new/worsened disability (odds ratio, 2.49; 1.54 to 4.04) compared with those who had mild or no dyspnoea. These associations were independent of age, sex and smoking status.

Furthermore, dyspnoea was independently correlated with low FEV1, high NT-proBNP, low physical performance and high BMI.

The finding that dyspnoea is common among older adults, independently associated with a higher risk of adverse outcomes, and is correlated with cardiopulmonary and physical performance impairments underscore the need for active monitoring and management of dyspnoea in older adults, researchers said.

Dyspnoea on exertion is a common and distressing symptom, although in older adults the symptom is nonspecific and complex given the presence of comorbidities. A previous report has suggested that dyspnoea overlaps between lung disease, heart disease, obesity and deconditioning in older adults. It is important that dyspnoea in older adults is studied as the symptom is disabling, as well as limits basic and instrumental activities of daily living. It also affects mobility and is associated with functional decline and frailty.  [Age Ageing 2014;43:319–26; Am J Respir Crit Care Med 2012;185:435–521; Ageing Res Rev 2014;15:94–9; Int J Clin Pract 2007;61:1481–91]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Audrey Abella, 16 Feb 2017
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) during acute respiratory infection episodes may increase the risk of acute myocardial infarction (MI), a recent study from Taiwan shows.
Pearl Toh, 22 Jun 2017
The next-generation ALK inhibitor brigatinib yielded high and durable responses in both whole-body and intracranial endpoints, with a median progression-free survival (PFS) of over 1 year in patients with ALK-positive non-small cell lung cancer (NSCLC) whose disease had progressed after crizotinib, according to the ALTA* trial.
Pearl Toh, 01 Mar 2016
Asthma development in young children may be associated with paracetamol exposure during maternal pregnancy or infancy, a new study on the MoBa* cohort showed.
Jairia Dela Cruz, 21 Jun 2017
Control treatment with montelukast may effectively reduce acute exacerbations in preschool children with mild persistent asthma, according to a study from Japan.